02.08.2012 10:12
Merck Serono, a division of Merck, Darmstadt, Germany, announced today the creation of Prexton Therapeutics, the first spin-off company resulting from its Entrepreneur Partnership Program launched in April 2012. Merck Serono will invest 2.1 million as seed funding. The company will be hosted in the offices and laboratory of Eclosion, a biotech start-up incubator located in Plan-les-Ouates, Geneva, and supported by the Geneva authorities.